Yahoo Finance Today’s Research Reports on GLG Life Tech, Microbix Biosystems, Nuvo Pharmaceuticals and Trillium Therapeutics
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
GLG Life Tech Corp.
https://rdinvesting.com/news/?ticker=GLG.TO
Microbix Biosystems Inc.
https://rdinvesting.com/news/?ticker=MBX.TO
Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO
Trillium Therapeutics Inc.
https://rdinvesting.com/news/?ticker=TRIL.TO
GLG Life Tech's stock had no change Wednesday, to close the day at $1.01. The stock recorded a trading volume of 400 shares, which was below its three months average volume of 10,347 shares. In the last year, GLG Life Tech's shares have traded in a range of 0.27 - 1.60. The share price has gained 274.07% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.17 is greater than its 200-day moving average of $1.00. Shares of GLG Life Tech have fallen approximately 9.03 percent year-to-date.
Access RDI’s GLG Life Tech Corp. Research Report at:
https://rdinvesting.com/news/?ticker=GLG.TO
On Wednesday, shares of Microbix Biosystems recorded a trading volume of 6,340 shares, which was below the three months average volume of 44,614 shares. The stock ended the day 1.85% lower at 0.27. The share price has gained 20.45% from its 52 week low with a 52 week trading range of 0.22 - 0.40. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.29 is below its 200-day moving average of $0.32. Shares of Microbix Biosystems have fallen approximately 13.11 percent year-to-date.
Access RDI’s Microbix Biosystems Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MBX.TO
Nuvo Pharmaceuticals’ stock had no change Wednesday, to close the day at $3.40. The stock recorded a trading volume of 884 shares, which was below its three months average volume of 13,725 shares. In the last year, Nuvo Pharmaceuticals’ shares have traded in a range of 3.21 - 6.43. The stock is currently trading 47.12% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.72 is below its 200-day moving average of $3.99. Shares of Nuvo Pharmaceuticals are trading at a Price to Earnings ratio of 12.01. Shares of Nuvo Pharmaceuticals have fallen approximately 8.11 percent year-to-date.
Access RDI’s Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO
On Wednesday, shares of Trillium Therapeutics recorded a trading volume of 4,250 shares, which was below the three months average volume of 18,380 shares. The stock ended the day 0.65% lower at 9.15. The share price has gained 73.95% from its 52 week low with a 52 week trading range of 5.26 - 16.80. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $9.78 is greater than its 200-day moving average of $8.85. Shares of Trillium Therapeutics have fallen approximately 1.65 percent year-to-date.
Access RDI’s Trillium Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TRIL.TO
Our Actionable Research on GLG Life Tech Corp. (TSX:GLG.TO), Microbix Biosystems Inc. (TSX:MBX.TO), Nuvo Pharmaceuticals Inc. (TSX:NRI.TO) and Trillium Therapeutics Inc. (TSX:TRIL.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
